{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:09:52Z","timestamp":1791047392489,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T00:00:00Z","timestamp":1244678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1245\/s10434-009-0555-9","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T10:51:09Z","timestamp":1244631069000},"page":"2617-2628","source":"Crossref","is-referenced-by-count":107,"title":["mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer"],"prefix":"10.1245","volume":"16","author":[{"given":"Yan-Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hou","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mang-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Guang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,11]]},"reference":[{"key":"555_CR1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471\u201384.","journal-title":"Cell."},{"key":"555_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4161\/cc.6.1.3675","volume":"6","author":"CK Tsang","year":"2007","unstructured":"Tsang CK, Zheng XF. TOR-in(g) the nucleus. Cell Cycle. 2007;6:25\u20139.","journal-title":"Cell Cycle."},{"key":"555_CR3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"DH Kim","year":"2002","unstructured":"Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163\u201375.","journal-title":"Cell."},{"key":"555_CR4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","volume":"6","author":"E Jacinto","year":"2004","unstructured":"Jacinto E, Loewith R, Schmidt A, Lin S, R\u00fcegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122\u20138.","journal-title":"Nat Cell Biol."},{"key":"555_CR5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/0008-5472.CAN-07-5635","volume":"68","author":"JR Graff","year":"2008","unstructured":"Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 2008;68:631\u20134.","journal-title":"Cancer Res."},{"key":"555_CR6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2007.04.002","volume":"13","author":"SG Dann","year":"2007","unstructured":"Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med. 2007;13:252\u20139.","journal-title":"Trends Mol Med."},{"key":"555_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9\u201322.","journal-title":"Cancer Cell."},{"key":"555_CR8","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1038\/sj.onc.1209888","volume":"25","author":"Y Mamane","year":"2006","unstructured":"Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene. 2006;25:6416\u201322.","journal-title":"Oncogene."},{"key":"555_CR9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","volume":"13","author":"GG Chiang","year":"2007","unstructured":"Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007;13:433\u201342.","journal-title":"Trends Mol Med."},{"key":"555_CR10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4161\/cbt.5.9.3175","volume":"5","author":"JE Dancey","year":"2006","unstructured":"Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther. 2006;5:1065\u201373.","journal-title":"Cancer Biol Ther."},{"key":"555_CR11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drudis.2006.12.008","volume":"12","author":"CK Tsang","year":"2007","unstructured":"Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007;12:112\u201324.","journal-title":"Drug Discov Today."},{"key":"555_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/07357900802314893","volume":"27","author":"YJ Zhang","year":"2009","unstructured":"Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, Fang JY. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest. 2009;27:273\u201385.","journal-title":"Cancer Invest."},{"key":"555_CR13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4161\/cc.8.7.8044","volume":"8","author":"DA Foster","year":"2009","unstructured":"Foster DA, Toschi A. Targeting mTOR with rapamycin: One dose does not fit all. Cell Cycle. 2009; 8:1026\u20139.","journal-title":"Cell Cycle."},{"key":"555_CR14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1517\/14728222.11.11.1429","volume":"11","author":"SA Haney","year":"2007","unstructured":"Haney SA. Expanding the repertoire of RNA interference screens for developing new anticancer drug targets. Expert Opin Ther Targets. 2007;11:1429\u201341.","journal-title":"Expert Opin Ther Targets."},{"key":"555_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/138920107783018426","volume":"8","author":"DR Micklem","year":"2007","unstructured":"Micklem DR, Lorens JB. RNAi screening for therapeutic targets in human malignancies. Curr Pharm Biotechnol. 2007;8:337\u201343.","journal-title":"Curr Pharm Biotechnol."},{"key":"555_CR16","first-page":"104","volume-title":"Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours","author":"SR Hamilton","year":"2001","unstructured":"Hamilton SR, Vogelstein B, Kudo S, Riboli E, Nakamura S, Hainaut P, et al. In: Hamilton SR, Aaltonen L, editors. Pathology and genetics of tumours of the digestive system. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001. p. 104\u201319."},{"key":"555_CR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-06-1560","volume":"13","author":"F Rojo","year":"2007","unstructured":"Rojo F, Najera L, Lirola J, Jim\u00e9nez J. Guzm\u00e1n M, Sabadell MD, et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 2007;13:81\u20139.","journal-title":"Clin Cancer Res."},{"key":"555_CR18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/07357900801944872","volume":"26","author":"YJ Zhang","year":"2008","unstructured":"Zhang YJ, Dai Q, Wu SM, Zhu HY, Shen GF, Li EL, et al. Susceptibility for NSAIDs-induced apoptosis correlates to p53 gene status in gastric cancer cells. Cancer Invest. 2008;26:868\u201377.","journal-title":"Cancer Invest."},{"key":"555_CR19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4161\/cbt.5.2.2317","volume":"5","author":"F Niola","year":"2006","unstructured":"Niola F, Evangelisti C, Campagnolo L, Massalini S, Bu\u00e9 MC, Mangiola A, et al. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther. 2006;5:174\u20139.","journal-title":"Cancer Biol Ther."},{"key":"555_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2006.11.008","volume":"251","author":"H Nozawa","year":"2007","unstructured":"Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett. 2007;251:105\u201313.","journal-title":"Cancer Lett."},{"key":"555_CR21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/mc.20402","volume":"47","author":"LS Faried","year":"2008","unstructured":"Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy. Mol Carcinog. 2008;47:446\u201357.","journal-title":"Mol Carcinog."},{"key":"555_CR22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00432-008-0529-5","volume":"135","author":"S Darb-Esfahani","year":"2009","unstructured":"Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, M\u00fcller B, et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol. 2009;135:933\u201341.","journal-title":"J Cancer Res Clin Oncol."},{"key":"555_CR23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/carcin\/bgg195","volume":"25","author":"K Khaleghpour","year":"2004","unstructured":"Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis. 2004;25:241\u20138.","journal-title":"Carcinogenesis."},{"key":"555_CR24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccr.2004.05.027","volume":"5","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell. 2004;5:519\u201323.","journal-title":"Cancer Cell."},{"key":"555_CR25","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1158\/0008-5472.CAN-07-0881","volume":"67","author":"G Armengol","year":"2007","unstructured":"Armengol G, Rojo F, Castellv\u00ed J, Iglesias C, Cuatrecasas M, Pons B, et al. 4E-binding protein 1: a key molecular \u201cfunnel factor\u201d in human cancer with clinical implications. Cancer Res. 2007;67:7551\u20135.","journal-title":"Cancer Res."},{"key":"555_CR26","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/cncr.22195","volume":"107","author":"J Castellvi","year":"2006","unstructured":"Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006;107:1801\u201311.","journal-title":"Cancer."},{"key":"555_CR27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10555-007-9077-8","volume":"26","author":"H Seeliger","year":"2007","unstructured":"Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007;26: 611\u201321.","journal-title":"Cancer Metastasis Rev."},{"key":"555_CR28","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","volume":"25","author":"JB Easton","year":"2006","unstructured":"Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006;25:6436\u201346.","journal-title":"Oncogene."},{"key":"555_CR29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14737140.6.1.131","volume":"6","author":"GV Georgakis","year":"2006","unstructured":"Georgakis GV, Younes A. From Rapa Nui to rapamycin: targeting PI3\u00a0K\/Akt\/mTOR for cancer therapy. Expert Rev Anticancer Ther. 2006;6:131\u201340.","journal-title":"Expert Rev Anticancer Ther."},{"key":"555_CR30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","volume":"169","author":"E Peponi","year":"2006","unstructured":"Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006;169:2171\u201380.","journal-title":"Am J Pathol."},{"key":"555_CR31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.canlet.2007.01.026","volume":"253","author":"G Hou","year":"2007","unstructured":"Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR\/p70S6\u00a0K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236\u201348.","journal-title":"Cancer Lett."},{"key":"555_CR32","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.yexcr.2006.05.001","volume":"312","author":"N Ke","year":"2006","unstructured":"Ke N, Zhou D, Chatterton JE, Liu G, Chionis J, Zhang J, et al. A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing. Exp Cell Res. 2006;312:2726\u201334.","journal-title":"Exp Cell Res."},{"key":"555_CR33","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.gt.3302929","volume":"14","author":"J George","year":"2007","unstructured":"George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther. 2007;14:790\u2013803.","journal-title":"Gene Ther."},{"key":"555_CR34","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.21570","volume":"45","author":"S Paranjpe","year":"2007","unstructured":"Paranjpe S, Bowen WC, Bell AW, Nejak-Bowen K, Luo JH, Michalopoulos GK. Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference. Hepatology. 2007;45:1471\u20137.","journal-title":"Hepatology."},{"key":"555_CR35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/hum.2006.17.751","volume":"17","author":"M Grzelinski","year":"2006","unstructured":"Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, H\u00f6bel S, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006;17:751\u201366.","journal-title":"Hum Gene Ther."},{"key":"555_CR36","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1172\/JCI33483","volume":"117","author":"DR Corey","year":"2007","unstructured":"Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest. 2007;117:3615\u201322.","journal-title":"J Clin Invest."},{"key":"555_CR37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2174\/156802607780487713","volume":"7","author":"TP Prakash","year":"2007","unstructured":"Prakash TP, Bhat B. 2\u2032-Modified oligonucleotides for antisense therapeutics. Curr Top Med Chem. 2007;7:641\u20139.","journal-title":"Curr Top Med Chem."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-009-0555-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-009-0555-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-009-0555-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:33:53Z","timestamp":1572953633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-009-0555-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,11]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1245\/s10434-009-0555-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,11]]}}}